Evidence links fine particulate matter (PM2.5) to Alzheimer’s disease (AD), but no community-based prospective cohort studies in older adults have evaluated the association between long-term exposure to PM2.5 and markers of AD neuropathology at autopsy.
Objective:
Using a well-established autopsy cohort and new spatiotemporal predictions of air pollution, we evaluated associations of 10-year PM2.5 exposure prior to death with Braak stage, Consortium to Establish a Registry for AD (CERAD) score, and combined AD neuropathologic change (ABC score).
Methods:
We used autopsy specimens (N = 832) from the Adult Changes in Thought (ACT) study, with enrollment ongoing since 1994. We assigned long-term exposure at residential address based on two-week average concentrations from a newly developed spatiotemporal model. To account for potential selection bias, we conducted inverse probability weighting. Adjusting for covariates with tiered models, we performed ordinal regression for Braak and CERAD and logistic regression for dichotomized ABC score.
Results:
10-year average (SD) PM2.5 from death across the autopsy cohort was 8.2 (1.9) μg/m3. Average age (SD) at death was 89 (7) years. Each 1μg/m3 increase in 10-year average PM2.5 prior to death was associated with a suggestive increase in the odds of worse neuropathology as indicated by CERAD score (OR: 1.35 (0.90, 1.90)) but a suggestive decreased odds of neuropathology as defined by the ABC score (OR: 0.79 (0.49, 1.19)). There was no association with Braak stage (OR: 0.99 (0.64, 1.47)).
Conclusion:
We report inconclusive associations between PM2.5 and AD neuropathology at autopsy among a cohort where 94% of individuals experienced 10-year exposures below the current EPA standard. Prior studies of AD risk factors and AD neuropathology are similarly inconclusive, suggesting alternative mechanistic pathways for disease or residual confounding.
PrinceM, Comas-HerreraA, KnappM, GuerchetM, KaragiannidouM (2016) World Alzheimer Report 2016. Improving healthcare for people living with dementia: Coverage, quality and costs now and in the future. Alzheimer’s Disease International, London.
NicholsE, SzoekeCEI, VollsetSE, AbbasiN, Abd-AllahF, AbdelaJ, AichourMTE, AkinyemiRO, AlahdabF, AsgedomSW (2019) Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol18, 88–106.
4.
SelkoeDJ (1991) The molecular pathology of Alzheimer’s disease. Neuron6, 487–498.
5.
Serrano-PozoA, FroschMP, MasliahE, HymanBT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med1, a006189.
6.
ChenH, KwongJC, CopesR, HystadP, van DonkelaarA, TuK, BrookJR, GoldbergMS, MartinRV, MurrayBJ, WiltonAS, KoppA, BurnettRT (2017) Exposure to ambient air pollution and the incidence of dementia: A population-based cohort study. Environ Int108, 271–277.
7.
PowerMC, AdarSD, YanoskyJD, WeuveJ (2016) Exposure to air pollution as a potential contributor to cognitive function, cognitive decline, brain imaging, and dementia: A systematic review of epidemiologic research. Neurotoxicology56, 235–253.
8.
OudinA, ForsbergB, AdolfssonAN, LindN, ModigL, NordinM, NordinS, AdolfssonR, NilssonL-G (2016) Traffic-related air pollution and dementia incidence in Northern Sweden: A longitudinal study. Environ Health Perspect124, 306–312.
9.
ChenH, KwongJC, CopesR, TuK, VilleneuvePJ, van DonkelaarA, HystadP, MartinRV, MurrayBJ, JessimanB, WiltonAS, KoppA, BurnettRT (2017) Living near major roads and the incidence of dementia, Parkinson’s disease, and multiple sclerosis: A population-based cohort study. Lancet389, 718–726.
10.
YuchiW, SbihiH, DaviesH, TamburicL, BrauerM (2020) Road proximity, air pollution, noise, green space and neurologic disease incidence: A population-based cohort study. Environ Health19, 8.
11.
Calderon-GarciduenasL, ReedW, MaronpotRR, Hen-riquez-RoldanC, Delgado-ChavezR, Calderon-Garci-duenasA, DragustinovisI, Franco-LiraM, Aragon-FloresM, SoltAC (2004) Brain inflammation and Alzheimer’s-like pathology in individuals exposed to severe air pollution. Toxicol Pathol32,, 650–658.
12.
Calderon-GarciduenasL, SoltAC, Henriquez-RoldanC, Torres-JardonR, NuseB, HerrittL, Villarreal-CalderonR, OsnayaN, StoneI, GarciaR, BrooksDM, Gonzalez-MacielA, Reynoso-RoblesR, Delgado-ChavezR, ReedW (2008) Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta42 and alpha-synuclein in children and young adults. Toxicol Pathol36, 289–310.
13.
Calderon-GarciduenasL, Franco-LiraM, Henriquez-RoldanC, OsnayaN, Gonzalez-MacielA, Reynoso-RoblesR, Villarreal-CalderonR, HerrittL, BrooksD, KeefeS (2010) Urban air pollution: Influences on olfactory function and pathology in exposed children and young adults. Exp Toxicol Pathol62, 91–102.
14.
Calderon-GarciduenasL, Mora-TiscarenoA, OntiverosE, Gomez-GarzaG, Barragan-MejiaG, BroadwayJ, ChapmanS, Valencia-SalazarG, JewellsV, MaronpotRR (2008) Air pollution, cognitive deficits and brain abnormalities: A pilot study with children and dogs. Brain Cogn68, 117–127.
15.
DurgaM, DevasenaT, RajasekarA (2015) Determination of LC50 and sub-chronic neurotoxicity of diesel exhaust nanoparticles. Environ Toxicol Pharmacol40, 615–625.
16.
BhattDP, PuigKL, GorrMW, WoldLE, CombsCK (2015) A pilot study to assess effects of long-term inhalation of airborne particulate matter on early Alzheimer-like changes in the mouse brain. PLoS One10, e0127102.
17.
KimSH, KnightEM, SaundersEL, CuevasAK, PopovechM, ChenL-C, GandyS (2012) Rapid doubling of Alzheimer’s amyloid-β40 and 42 levels in brains of mice exposed to a nickel nanoparticle model of air pollution. F1000Research1, 70.
18.
BlockML, Calderon-GarciduenasL (2009) Air pollution: Mechanisms of neuroinflammation and CNS disease. Trends Neurosci32, 506–516.
19.
JayarajRL, RodriguezEA, WangY, BlockML (2017) Outdoor ambient air pollution and neurodegenerative diseases: The neuroinflammation hypothesis. Curr Environ Health Rep4, 166–179.
20.
HeusinkveldHJ, WahleT, CampbellA, WesterinkRHS, TranL, JohnstonH, StoneV, CasseeFR, SchinsRPF (2016) Neurodegenerative and neurological disorders by small inhaled particles. Neurotoxicology56, 94–106.
21.
GalaskoD, MontineTJ (2010) Biomarkers of oxidative damage and inflammation in Alzheimer’s disease. Biomarkers Med4, 27–36.
Calderón-GarcidueñasL, Gónzalez-MacielA, Reynoso-RoblesR, Delgado-ChávezR, MukherjeePS, KuleszaRJ, Torres-JardónR, Ávila-RamírezJ, Villarreal-RíosR (2018) Hallmarks of Alzheimer disease are evolving relentlessly in Metropolitan Mexico City infants, children and young adults. APOE4 carriers have higher suicide risk and higher odds of reaching NFT stage V at ≤ 40 years of age. Environ Res164, 475–487.
24.
IaccarinoL, La JoieR, Lesman-SegevOH, LeeE, Ha-nnaL, AllenIE, HillnerBE, SiegelBA, WhitmerRA, CarrilloMC, GatsonisC, RabinoviciGD (2020) Association between ambient air pollution and amyloid positron emission tomography positivity in older adults with cognitive impairment. JAMA Neurol, doi: 10.1001/jamaneurol.2020.3962
25.
KukullWA, HigdonR, BowenJD, McCormickWC, TeriL, SchellenbergGD, van BelleG, JolleyL, LarsonEB (2002) Dementia and Alzheimer disease incidence: A prospective cohort study. Arch Neurol59, 1737–1746.
26.
KellerJP, OlivesC, KimS-Y, SheppardL, SampsonPD, SzpiroAA, OronAP, LindströmJ, VedalS, KaufmanJD (2015) A unified spatiotemporal modeling approach for predicting concentrations of multiple air pollutants in the multi-ethnic study of atherosclerosis and air pollution. Environ Health Perspect123, 301–309.
27.
SampsonPD, SzpiroAA, SheppardL, LindströmJ, KaufmanJD (2011) Pragmatic estimation of a spatio-temporal air quality model with irregular monitoring data. Atmos Environ45, 6593–6606.
28.
SzpiroAA, SampsonPD, SheppardL, LumleyT, AdarSD, KaufmanJD (2010) Predicting intra-urban variation in air pollution concentrations with complex spatio-temporal dependencies. Environmetrics21, 606–631.
29.
SonnenJA, LarsonEB, CranePK, HaneuseS, LiG, SchellenbergGD, CraftS, LeverenzJB, MontineTJ (2007) Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol62, 406–413.
30.
MirraSS, HeymanA, McKeelD, SumiSM, CrainBJ, BrownleeLM, VogelFS, HughesJP, van BelleG, BergL (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology41, 479–486.
MontineTJ, PhelpsCH, BeachTG, BigioEH, CairnsNJ, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, TrojanowskiJQ, VintersHV, HymanBT (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol123, 1–11.
33.
HymanBT, PhelpsCH, BeachTG, BigioEH, CairnsNJ, CarrilloMC, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, ThiesB, TrojanowskiJQ, VintersHV, MontineTJ (2012) National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement8, 1–13.
34.
TsuangD, SimpsonKL, LiG, BarnhartRL, EdlandSD, BowenJ, McCormickW, TeriL, NochlinD, LarsonEB, ThompsonML, LeverenzJB (2005) Evaluation of selection bias in an incident-based dementia autopsy case series. Alzheimer Dis Assoc Disord19, 67–73.
35.
HaneuseS, SchildcroutJ, CraneP, SonnenJ, BreitnerJ, LarsonE (2009) Adjustment for selection bias in observational studies with application to the analysis of autopsy data. Neuroepidemiology32, 229–239.
36.
ColeSR, HernánMA (2008) Constructing inverse probability weights for marginal structural models. Am J Epidemiol168, 656–664.
37.
HernanMA, Hernandez-DiazS, RobinsJM (2004) A structural approach to selection bias. Epidemiology15, 615–625.
JackCR, Jr., KnopmanDS, JagustWJ, ShawLM, AisenPS, WeinerMW, PetersenRC, TrojanowskiJQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol9, 119–128.
40.
BraakH, Del TrediciK (2015) The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease. Brain138, 2814–2833.
41.
SternY (2002) What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc8, 448–460.
42.
SatzP (1993) Brain reserve capacity on symptom onset after brain injury: A formulation and review of evidence for threshold theory. Neuropsychology7, 273.
43.
KatzmanR, AronsonM, FuldP, KawasC, BrownT, MorgensternH, FrishmanW, GidezL, EderH, OoiWL (1989) Development of dementing illnesses in an 80-year-old volunteer cohort. Ann Neurol25, 317–324.
44.
KatzmanR (1993) Education and the prevalence of dementia and Alzheimer’s disease. Neurology43, 13–20.
GhebremedhinE, SchultzC, ThalDR, RübU, OhmTG, BraakE, BraakH (2001) Gender and age modify the association between APOE and AD-related neuropathology. Neurology56, 1696–1701.
47.
BarnesLL, WilsonRS, BieniasJL, SchneiderJA, EvansDA, BennettDA (2005) Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry62, 685–691.
48.
CloughertyJE (2010) A growing role for gender analysis in air pollution epidemiology. Environ Health Perspect118, 167–176.
49.
ReimanEM, ChenK, LiuX, BandyD, YuM, LeeW, AyutyanontN, KepplerJ, ReederSA, LangbaumJB, AlexanderGE, KlunkWE, MathisCA, PriceJC, AizensteinHJ, DeKoskyST, CaselliRJ (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A106, 6820–6825.
50.
SchmechelDE, SaundersAM, StrittmatterWJ, CrainBJ, HuletteCM, JooSH, Pericak-VanceMA, GoldgaberD, RosesAD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A90, 9649–9653.
51.
PostupnaN, KeeneCD, CranePK, Gonzalez-CuyarLF, SonnenJA, HewittJ, RiceS, HowardK, MontineKS, LarsonEB, MontineTJ (2015) Cerebral cortical Aβ 42 and PHF-τ in 325 consecutive brain autopsies stratified by diagnosis, location, and APOE. J Neuropathol Exp Neurol74, 100–109.
52.
TiraboschiP, HansenLA, MasliahE, AlfordM, ThalLJ, Corey-BloomJ (2004) Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology62, 1977–1983.
53.
Pope IIICA, ColemanN, PondZA, BurnettRT (2019) Fine particulate air pollution and human mortality: 25+years of cohort studies. Environ Res183, 108924.
54.
BraakH, ThalDR, GhebremedhinE, Del TrediciK (2011) Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol70, 960–969.
55.
O’NeillMS, JerrettM, KawachiI, LevyJI, CohenAJ, GouveiaN, WilkinsonP, FletcherT, CifuentesL, SchwartzJ (2003) Health, wealth, and air pollution: Advancing theory and methods. Environ Health Perspect111, 1861–1870.
56.
KoepsellTD, KurlandBF, HarelO, JohnsonEA, ZhouXH, KukullWA (2008) Education, cognitive function, and severity of neuropathology in Alzheimer disease. Neurology70, 1732–1739.
57.
HajatA, Diez-RouxAV, AdarSD, AuchinclossAH, LovasiGS, O’NeillMS, SheppardL, KaufmanJD (2013) Air pollution and individual and neighborhood socioeconomic status: Evidence from the Multi-Ethnic Study of Atherosclerosis (MESA). Environ Health Perspect121, 1325–1333.
58.
PerlinSA, WongD, SextonK (2001) Residential proximity to industrial sources of air pollution: Interrelationships among race, poverty, and age. J Air Waste Manag Assoc51, 406–421.
59.
JonesMR, Diez-RouxAV, HajatA, KershawKN, O’NeillMS, GuallarE, PostWS, KaufmanJD, Navas-AcienA (2014) Race/ethnicity, residential segregation, and exposure to ambient air pollution: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Public Health104, 2130–2137.
60.
SchlesingerD, GrinbergLT, AlbaJG, NaslavskyMS, LicinioL, FarfelJM, SuemotoCK, de Lucena FerrettiRE, LeiteREP, de AndradeMP, dos SantosACF, BrentaniH, PasqualucciCA, NitriniR, Jacob-FilhoW, ZatzM (2011) African ancestry protects against Alzheimer’s disease-related neuropathology. Mol Psychiatry18, 79–85.
61.
CourtJA, JohnsonM, ReligaD, KeverneJ, KalariaR, JarosE, McKeithIG, PerryR, NaslundJ, PerryEK (2005) Attenuation of Aβ deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking. Neuropathol Appl Neurobiol31, 522–535.
62.
Moreno-GonzalezI, EstradaLD, Sanchez-MejiasE, SotoC (2013) Smoking exacerbates amyloid pathology in a mouse model of Alzheimer’s disease. Nat Commun4, 1–10.
63.
RovioS, KåreholtI, HelkalaE-L, ViitanenM, WinbladB, TuomilehtoJ, SoininenH, NissinenA, KivipeltoM (2005) Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol4, 705–711.
64.
BlondellSJ, Hammersley-MatherR, VeermanJL (2014) Does physical activity prevent cognitive decline and dementia?: A systematic review and meta-analysis of longitudinal studies. BMC Public Health14, 510.
65.
BuchmanAS, SchneiderJA, WilsonRS, BieniasJL, BennettDA (2006) Body mass index in older persons is associated with Alzheimer disease pathology. Neurology67, 1949–1954.
66.
HsuDC, MorminoEC, SchultzAP, AmariglioRE, DonovanNJ, RentzDM, JohnsonKA, SperlingRA, MarshallGA (2016) Lower late-life body-mass index is associated with higher cortical amyloid burden in clinically normal elderly. J Alzheimers Dis53, 1097–1105.
67.
GuY, ScarmeasN, CosentinoS, BrandtJ, AlbertM, BlackerD, DuboisB, SternY (2014) Change in body mass index before and after Alzheimer’s disease onset. Curr Alzheimer Res11, 349–356.
68.
MatsuzakiT, SasakiK, TanizakiY, HataJ, FujimiK, MatsuiY, SekitaA, SuzukiSO, KanbaS, KiyoharaY, IwakiT (2010) Insulin resistance is associated with the pathology of Alzheimer disease. Neurology75, 764–770.
69.
PruzinJJ, NelsonPT, AbnerEL, ArvanitakisZ (2018) Review: Relationship of type 2 diabetes to human brain pathology. Neuropathol Appl Neurobiol44, 347–362.
70.
BeeriMS, SilvermanJM, DavisKL, MarinD, GrossmanHZ, SchmeidlerJ, PurohitDP, PerlDP, DavidsonM, MohsRC (2005) Type 2 diabetes is negatively associated with Alzheimer’s disease neuropathology. J Gerontol A Biol Sci60, 471–475.
71.
RajagopalanS, BrookRD (2012) Air pollution and type 2 diabetes: Mechanistic insights. Diabetes61, 3037–3045.
72.
AuchinclossAH, Diez RouxAV, DvonchJT, BrownPL, BarrRG, DaviglusML, GoffDC, KaufmanJD, O’NeillMS (2008) Associations between recent exposure to ambient fine particulate matter and blood pressure in the Multi-Ethnic Study of Atherosclerosis (MESA). Environ Health Perspect116, 486–491.
73.
ChenH, BurnettRT, KwongJC, VilleneuvePJ, GoldbergMS, BrookRD, van DonkelaarA, JerrettM, MartinRV, KoppA (2013) Spatial association between ambient fine particulate matter and incident hypertension. Circulation129, 562–569.
74.
PetrovitchH, WhiteLR, IzmirilianG, RossGW, HavlikRJ, MarkesberyW, NelsonJ, DavisDG, HardmanJ, FoleyDJ (2000) Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: The HAAS. Neurobiol Aging21, 57–62.
75.
BeeriMS, RappM, SilvermanJM, SchmeidlerJ, GrossmanHT, FallonJT, PurohitDP, PerlDP, SiddiquiA, LesserG, RosendorffC, HaroutunianV (2006) Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology66, 1399–1404.
76.
BeachTG, WilsonJR, SueLI, NewellA, PostonM, CisnerosR, PandyaY, EshC, ConnorDJ, SabbaghM (2007) Circle of Willis atherosclerosis: Association with Alzheimer’s disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol113, 13–21.
77.
ZlokovicBV (2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci12, 723–738.
78.
HullmannM, AlbrechtC, van BerloD, Gerlofs-NijlandME, WahleT, BootsAW, KrutmannJ, CasseeFR, BayerTA, SchinsRPF (2017) Diesel engine exhaust accelerates plaque formation in a mouse model of Alzheimer’s disease. Part Fibre Toxicol14, 1–14.
79.
LevesqueS, SuraceMJ, McDonaldJ, BlockML (2011) Air pollution&the brain: Subchronic diesel exhaust exposure causes neuroinflammation and elevates early markers of neurodegenerative disease. J Neuroinflammation8, 105.
80.
JangS, KimEW, ZhangY, LeeJ, ChoSY, HaJ, KimH, KimE (2018) Particulate matter increases beta-amyloid and activated glial cells in hippocampal tissues of transgenic Alzheimer’s mouse: Involvement of PARP-1. Biochem Biophys Res Commun500, 333–338.
81.
CacciottoloM, MorganTE, SaffariAA, ShirmohammadiF, FormanHJ, SioutasC, FinchCE (2020) Traffic-related air pollutants (TRAP-PM) promote neuronal amyloidogenesis through oxidative damage to lipid rafts. Free Radic Biol Med147, 242–251.
82.
GraySL, AndersonML, DublinS, HanlonJT, HubbardR, WalkerR, YuO, CranePK, LarsonEB (2015) Cumulative use of strong anticholinergics and incident dementia: A prospective cohort study. JAMA Intern Med175, 401–407.
83.
CranePK, WalkerRL, SonnenJ, GibbonsLE, MelroseR, HassenstabJ, KeeneCD, PostupnaN, MontineTJ, LarsonEB (2016) Glucose levels during life and neuropathologic findings at autopsy among people never treated for diabetes. Neurobiol Aging48, 72–82.
84.
TsuangD, LarsonEB, LiG, ShoferJB, MontineKS, ThompsonML, SonnenJA, CranePK, LeverenzJB, MontineTJ (2010) Association between lifetime cigarette smoking and Lewy body accumulation. Brain Pathol20, 412–418.
SabbaghMN, TyasSL, EmerySC, HansenLA, AlfordMF, ReidRT, TiraboschiP, ThalLJ (2005) Smoking affects the phenotype of Alzheimer disease. Neurology64, 1301–1303.
87.
UlrichJ, Johannson-LocherG, SeilerWO, StahelinHB (1997) Does smoking protect from Alzheimer’s disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol94, 450–454.
88.
Hellström-LindahlE, MousaviM, RavidR, NordbergA (2004) Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer’s patients. Neurobiol Dis15, 351–360.
89.
EzzatiM, LopezAD (2003) Estimates of global mortality attributable to smoking in 2000. Lancet362, 847–852.
90.
KellerJN (2006) Age-related neuropathology, cognitive decline, and Alzheimer’s disease. Ageing Res Rev5, 1–13.
91.
SchikowskiT, VossoughiM, VierkötterA, SchulteT, TeichertT, SugiriD, FehselK, TzivianL, BaeI-s, RanftU, HoffmannB, Probst-HenschN, HerderC, KrämerU, LuckhausC (2015) Association of air pollution with cognitive functions and its modification by APOE gene variants in elderly women. Environ Res142, 10–16.
92.
Calderón-GarcidueñasL, Mora-TiscareñoA, Franco-LiraM, ZhuH, LuZ, SolorioE, Torres-JardónR, D’AngiulliA (2015) Decreases in short term memory, IQ, and altered brain metabolic ratios in urban apolipoprotein ɛ4 children exposed to air pollution. J Alzheimers Dis45, 757–770.
93.
Calderon-GarciduenasL, KavanaughM, BlockM, D’AngiulliA, Delgado-ChavezR, Torres-JardonR, Gonzalez-MacielA, Reynoso-RoblesR, OsnayaN, Villarreal-CalderonR, GuoR, HuaZ, ZhuH, PerryG, DiazP (2012) Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults. J Alzheimers Dis28, 93–107.
94.
CacciottoloM, WangX, DriscollI, WoodwardN, SaffariA, ReyesJ, SerreML, VizueteW, SioutasC, MorganTE, GatzM, ChuiHC, ShumakerSA, ResnickSM, EspelandMA, FinchCE, ChenJC (2017) Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models. Transl Psychiatry7, 1022.
95.
Calderon-GarciduenasL, JewellsV, Galaz-MontoyaC, van ZundertB, Perez-CalatayudA, Ascencio-FerrelE, Valencia-SalazarG, Sandoval-CanoM, CarlosE, SolorioE, Acuna-AyalaH, Torres-JardonR, D’AngiulliA (2016) Interactive and additive influences of Gender, BMI and Apolipoprotein 4 on cognition in children chronically exposed to high concentrations of PM2.5 and ozone. APOE 4 females are at highest risk in Mexico City. Environ Res150, 411–422.
96.
WuYC, LinYC, YuHL, ChenJH, ChenTF, SunY, WenLL, YipPK, ChuYM, ChenYC (2015) Association between air pollutants and dementia risk in the elderly. Alzheimers Dement1, 220–228.
MorrisJC, StorandtM, McKeelDW, Jr., RubinEH, PriceJL, GrantEA, BergL (1996) Cerebral amyloid deposition and diffuse plaques in “normal” aging: Evidence for presymptomatic and very mild Alzheimer’s disease. Neurology46, 707–719.
99.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCR, Jr., KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
100.
AizensteinHJ, NebesRD, SaxtonJA, PriceJC, MathisCA, TsopelasND, ZiolkoSK, JamesJA, SnitzBE, HouckPR (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol65, 1509–1517.
101.
HuletteCM, Welsh-BohmerKA, MurrayMG, SaundersAM, MashDC, McIntyreLM (1998) Neuropathological and neuropsychological changes in “normal” aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol57, 1168–1174.
102.
PriceJL, MorrisJC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol45, 358–368.
103.
JansenWJ, OssenkoppeleR, KnolDL, TijmsBM, ScheltensP, VerheyFR, VisserPJ; Amyloid Biomarker Study Group, AaltenP,
AarslandD,
et al. (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA313, 1924–1938.
104.
ArriagadaPV, MarzloffK, HymanBT (1992) Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease. Neurology42, 1681–1688.
105.
PostupnaN, RoseSE, BirdTD, Gonzalez-CuyarLF, SonnenJA, LarsonEB, KeeneCD, MontineTJ (2012) Novel antibody capture assay for paraffin-embedded tissue detects wide-ranging amyloid beta and paired helical filament-tau accumulation in cognitively normal older adults. Brain Pathol22, 472–484.
106.
KeeneCD, WilsonAM, KilgoreMD, BrunerLT, PostupnaNO, DarvasM (2019) Luminex-based quantification of Alzheimer’s disease neuropathologic change in formalin-fixed post-mortem human brain tissue. Lab Invest99, 1056–1067.
107.
ClarkTG, AltmanDG, De StavolaBL (2002) Quantification of the completeness of follow-up. Lancet359, 1309–1310.
108.
Gilmore-BykovskyiAL, JinY, GleasonC, Flowers-BentonS, BlockLM, Dilworth-AndersonP, BarnesLL, ShahMN, ZuelsdorffM (2019) Recruitment and retention of underrepresented populations in Alzheimer’s disease research: A systematic review. Alzheimers Dement (N Y)5, 751–770.
109.
CranePK, WalkerR, HubbardRA, LiG, NathanDM, ZhengH, HaneuseS, CraftS, MontineTJ, KahnSE (2013) Glucose levels and risk of dementia. N Engl J Med369, 540–548.
110.
GraySL, AndersonML, HanlonJT, DublinS, WalkerRL, HubbardRA, YuO, MontineTJ, CranePK, SonnenJA, KeeneCD, LarsonEB (2018) Exposure to strong anticholinergic medications and dementia-related neuropathology in a community-based autopsy cohort. J Alzheimers Dis65, 607–616.
